Minimize treatment failure, Maximize long-term HBV suppression

Line probe assay for simultaneous detection of hepatitis B virus wild-type motif, lamivudine, telbivudine, emtricitabine, adefovir, and entecavir resistance-associated mutations.

Contact sales for information
For research use only

Product number 81382

20 Tests (Amplification kits included)
Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Contact sales for information
  • Details
  • Conditions of sale
  • Documentation
  • Insights
  • FAQ
  • Product inquiry
  • Related products
  • Details

    Features & Benefits

    • Earliest detection of mutants:
    • Highly sensitive detection at single nucleotide level of mixtures of wild-type and mutants, identifying the appearance of mutants earlier than sequencing and viral load assays
    • Lower limit of detection of 990 copies/ml
    • Allowing rapid and effective HBV suppression by early adoption to the most suited therapy
    • All the necessary information in one assay:
    • Allows simultaneous detection of all clinically relevant HBV polymerase wild-type and drug-induced mutations associated with lamivudine, emtricitabine, telbivudine, adefovir and tenofovir resistance as well as known compensatory mutations (codons 80, 173, 180, 181, and 204)
    • Identifies amino acid changes in the overlapping reading frame of HBsAg (codons 171, 172, 195, 196, 198, and 199)
    • Optimized for 8 known HBV genotypes (A-H)
    • Low chance of errors and limited hands-on time:
    • Easy to perform and robust assay
    • Amplicon can also be used for INNO-LIPA HBV GT
    • Fully automated processing of the strips possible with Auto-LIPA™ 48 and AutoBlot 3000H.
    • Objective and automated reading and interpretation of strips possible using LiRAS® for Infectious Diseases.
  • Conditions of sale

    To read the end user conditions of sale for this product please visit our Resource center.

  • Insights

  • FAQ

  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: